Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19thPRNewsWire • 03/13/25
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025PRNewsWire • 02/25/25
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 02/20/25
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/13/25
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?Zacks Investment Research • 01/02/25
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory PapillomatosisPRNewsWire • 12/30/24
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred StockPRNewsWire • 12/27/24
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market SessionBenzinga • 08/15/24
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business UpdatesPRNewsWire • 08/14/24
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14thPRNewsWire • 08/09/24
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to DeclineZacks Investment Research • 08/07/24
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy LaunchPRNewsWire • 08/06/24
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy LaunchPRNewsWire • 07/23/24